Sources New England Journal of Medicine: Once-Weekly Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine: Tirzepatide Once Weekly for the Treatment of Obesity Diabetes, Obesity and Metabolism: A Journal of Pharmacology and Therapeutics: Semaglutide for the treatment of overweight and obesity: A review JAMA Network: Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity American Diabetes Association: Standards of Medical Care in Diabetes, 2025 Harvard Health Publishing: GLP-1 diabetes and weight-loss drug side effects: Ozempic face and more University of Illinois Chicago: What efficacy data are available on the use of tirzepatide for obesity
Semaglutide helps to decrease appetite and delays stomach emptying, keeping you satisfied longer
doi: 10.1016/j.diabres.2018.02.023 2
MeAgain is a GLP-1-first daily tracker and companion built around what people actually manage after the prescription exists: shot day, food noise, protein, fiber, water, symptoms, dose changes, stalls, progress photos, and the days between doses
The expected outcomes of Semaglutide treatment will vary depending on the individuals starting weight
Your healthcare provider can conduct tests to rule out other potential causes and ensure that your treatment plan is optimized for your overall health
